Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
11:35am, Tuesday, 06'th Aug 2024
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
BioMarin: Q2 Revenue Soars 20%
10:05am, Tuesday, 06'th Aug 2024
Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript
09:35pm, Monday, 05'th Aug 2024
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2024 Results Conference Call August 5, 2024 5:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Ch
BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say
07:01pm, Monday, 05'th Aug 2024
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
06:15pm, Monday, 05'th Aug 2024
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.54 per share a year ago.
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
04:03pm, Monday, 05'th Aug 2024
Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 billion (+14% Y/Y and +19% at Constant Currency Y/Y) Second Qua
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
04:01pm, Monday, 05'th Aug 2024
Strategic Focus will Reduce Operating Expenses with the Goal of Achieving ROCTAVIAN Profitability by End of 2025 BioMarin to Provide Continued Monitoring and Support to Those Treated in Clinical Tri
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
10:20am, Wednesday, 31'st Jul 2024
Evaluate the expected performance of BioMarin (BMRN) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
04:05pm, Wednesday, 24'th Jul 2024
Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, Calif. , July 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BM
Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again
01:11pm, Wednesday, 24'th Jul 2024
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET
08:00am, Tuesday, 23'rd Jul 2024
SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
11:06am, Monday, 22'nd Jul 2024
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?
09:47am, Monday, 15'th Jul 2024
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with Achondroplasia Phase 2 and 3 Data on VOXZOG
Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression Maintained Four Years Post-ROCTAVIAN Infusion Additional Data Show Meani
